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SUPPORTIVE CARE A. Acute and Delayed Emesis Prophylaxis: The IC
regimen is predicted to cause acute emesis in 60% to 90% of patients. 21 The studies reviewed reported nausea and vomiting (all grades) in 1% to 45% of patients and severe (grade 3 or 4) nausea or vomiting in only 1% to 18% of patients. [1] [2] [3] [4] [5] [6] 8, [10] [11] [12] [13] [14] [16] [17] [18] Although carboplatin is reported to cause delayed nausea or emesis similar to cisplatin, the mechanism of action and clinical course of carboplatin-induced nausea and vomiting differ from cisplatin. 22, 23 Analysis of urinary 5-hydroxyindole acetic acid (5-HIAA) excretion indicates carboplatin causes a lower peak level, but more prolonged release, of serotonin than cisplatin. The clinical course of carboplatin-induced emesis refl ects this pattern of serotonin release. Carboplatin-induced emesis usually begins 6 to 7 hours after drug administration and may persist for up to 120 hours.
Although not well documented in the literature, some clinicians divide the daily antiemetic dose into 2 doses on days when carboplatin is administered. Appropriate acute emesis prophylaxis includes a serotonin antagonist and a corticosteroid plus or minus a neurokinin antagonist in selected patients. [24] [25] [26] One of the following regimens is suggested:
1. Ondansetron 16 mg to 24 mg, dexamethasone 12 mg orally (PO) ± aprepitant 125 mg given PO 60 minutes before IC on day 1. 2. Granisetron 1 mg to 2 mg, dexamethasone 12 mg PO ± aprepitant 125 mg given PO 60 minutes before IC on day 1. 3. Dolasetron 100 mg to 200 mg, dexamethasone 12 mg PO ± aprepitant 125 mg given PO 60 minutes before IC on day 1. 4. Palonosetron 0.25 mg IV and dexamethasone 12 mg PO ± aprepitant 125 mg given PO 60 minutes before IC on day 1. The antiemetic therapy should continue for an additional 2 days. Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. 24-26 A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid and dopamine antagonist combination most appropriate for follow-up therapy. 27 One of the following regimens is suggested: [28] [29] [30] [31] [32] may be effective in treating breakthrough nausea, however none of these reports found the improvement to be statistically signifi cant. C. Diarrhea: Diarrhea is a frequent consequence of irinotecan therapy and can be severe and potentially fatal. Severe cases of irinotecan-induced diarrhea have been documented in individuals with Gilbert's syndrome, which is caused by homozygosity for polymorphisms of the UDPglucuronyltransferase gene: UGT1A1*28. [33] [34] [35] [36] In the studies reviewed, patients possessing these polymorphisms demonstrated an increased rate of hematologic toxicity and more severe diarrhea. 1, 11, 12, 18 Irinotecan may cause 2 severe, life-threatening forms of diarrhea. Early diarrhea usually occurs during the fi rst 24 hours of receiving irinotecan and is characterized by cholinergic symptoms, such as increased salivation, diaphoresis, and abdominal cramping. This early form is usually responsive to IV atropine (0.25 mg to 1 mg). Late diarrhea, occurring more than 24 hours after treatment, may lead to dehydration, electrolyte imbalances, or sepsis. This late form of diarrhea should be treated with loperamide. 37 Patients should receive a prescription for an antidiarrheal agent for use at the onset of diarrhea. The standard recommendation is loperamide 4 mg PO at the onset of diarrhea, followed by 2 mg PO after each unformed stool, or as often as every 2 hours for 24 hours. 38 Patients should be counseled to 39 : 1. Monitor bowel movements. 2. Treat grade 1 or 2 diarrhea (increase of >7 stools per day or nocturnal stools) with loperamide and oral rehydration. 3. Immediately seek advice from their physician, pharmacist, or nurse for persistent (> 4 hours) grade 1 or 2 diarrhea or grade 3 diarrhea (increase of >7 stools per day or incontinence or symptoms of dehydration). 4. Discontinue loperamide when they have been diarrhea-free for at least 12 hours. The studies reviewed reported grade 3 or 4 diarrhea in 2% to 23% of patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [16] [17] [18] [19] D. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco-economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 40, 41 In the IC trials reviewed, febrile neutropenia was reported in 1% to 19% of patients 1, 2, 4, 8, 9, 13, 16, 18, 19 ; severe neutropenia (grade 3 or 4) was reported in 2% to 55% of patients. 2 43, 44 There was one treatment-related death due to anaphylactic shock after IV administration of carboplatin 17 and several reports of allergic reactions (grade 1-2) 1% to 4% 10 and rash (grade 1-2) 2% 16 in the studies reviewed. Volume 49, July-August 2014
Carboplatin hypersensitivity reactions generally develop in patients who have been extensively pretreated with the agent. 45 With more prolonged use (ie, >6 courses), or if utilized in previously treated patients, the incidence of reactions is likely to be considerably greater. 45 Carboplatin is reported to cause hypersensitivity reactions in 12% to 19% of patients. 46 One study reported the incidence as high as 27% in patients with gynecologic cancers receiving 7 or more courses of carboplatin. 45 Mild hypersensitivity reactions, consisting of localized itching, and mild erythema of the palms and/or soles necessitates stopping the infusion and possible administration of an antihistamine and/or a corticosteroid before continuing the infusion. 47 Upon symptom resolution, these patients may resume treatment. Moderate to severe reactions, consisting of more severe itching, diffuse erythema, rigor, facial swelling, throat and/or chest tightness, tachycardia, bronchospasm, hypertension, or hypotension usually require permanent discontinuation of carboplatin treatment and prompt administration of parenteral corticosteroids and antihistamines. 47 The decision to re-challenge or discontinue treatment after a moderate to severe reaction occurs is dependent upon the severity of the reaction and other clinical factors. 46 
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs. nci.nih .gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. [1] [2] [3] 10, 11, 16, 17 b. Greater than 4,000 cells/mcL and less than 12,000 cells/mcL. 6,14 c. Greater than 3,000 cells/mcL. 7 2. Absolute neutrophil count (ANC): a. Greater than or equal to 1,500 g/ dL. 4, 5, 8, 10, 12, 13, 18 b. Greater than 2,000 cells/mcL. 6, 11, 14 3. Platelet count greater than or equal to 100,000 cells/mcL. 1-8,11-14,16-18 4 . Serum creatinine a. Less than or equal to 1.25 times upper limit of normal (ULN). 1,2,5 b. Less than 1.5 mg/dL. 4, 6, 11 c. Creatinine clearance (CrCl) greater than or equal to 50 mL/min. 6,14 d. Less than 1.5 times ULN. 7, 13 e. Less than or equal to ULN. 10 f. CrCl greater than or equal to 40 mL/ min. 11,16 g. Less than or equal to 2 mg/dL. 12 h. Less than or equal to 1.2 mg/dL. 14 i. Less than or equal to 2 mg/dL or CrCl greater than 60 mL/min. 18 
A. Cardiovascular

Serum bilirubin
a. Less than or equal to 1.25 times ULN. [1] [2] [3] 5 b. Less than or equal to 1.5 mg/dL. 4, 7, 8, 10, [12] [13] [14] 16 c. Less than ULN. 6, 11 d. Less than or equal to 25 micromol/L. 17 e. Less than or equal to 1.5 times ULN. 18 6. ALT/AST a. Less than or equal to 2 times ULN. 3, 6, 7, 10, 11, 16, 17 b. Less than or equal to 3 times ULN. 4, 5 c. AST less than or equal to 2.5 times ULN or less than 5 times ULN if liver metastases. 8, 12, 13 d. AST/ALT less than or equal to 100 IU/L. 14 7 . Hemoglobin a. Greater than 9 g/dL. 2, 6, [10] [11] [12] b. Greater than or equal to 10 g/dL. 3, 4, 17 c. Greater than or equal to 9.5 g/dL. 14,16 8 . Arterial oxygen pressure (PaO2) a. Greater than or equal to 70 mm Hg. 3, 17 b. Greater than or equal to 60 mm Hg. 6, 11 In clinical practice, a pretreatment ANC of 1,000 cells/mcL and platelets of 75,000 cells/mcL are usually considered acceptable.
DOSAGE MODIFICATIONS A. Renal Function
1. Carboplatin: If doses are calculated according to the patient's renal function, additional dose adjustments for renal insuffi ciency are not necessary. 48 Carboplatin doses are commonly calculated using an equation based on the method of Calvert et al. 49 Calvert's group showed that the carboplatin dose in milligrams can be calculated using a desired area under the time vs concentration curve (AUC) and the patient's glomerular fi ltration rate (GFR 
